Vanderbilt University's venture capital investment strategy, managed through its diversified endowment, focuses on long-term partnerships with world-class managers and includes being an early institutional investor in venture capital. Additionally, the Vanderbilt Venture Partners (VVP) program specifically targets early-stage (seed and Series A) startups from Vanderbilt's research, aiming to commercialize scientific innovations and often being the first institutional investor in unique opportunities.
Portfolio
4
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Stage Distribution
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Cambium Biomaterials | Series B | $100M | Jan 2026 |
| Foundation Health | Series A | $20M | Oct 2025 |
| Zeno Power | Series B | $50M | May 2025 |
| Arcturus | Seed | $2.3M | — |
Top Co-Investors
Hanaco Ventures1 shared
Balerion Space Ventures1 shared
8VC1 shared
MVP Ventures1 shared
Lockheed Martin Ventures1 shared
GSBackers1 shared
Veteran Ventures Capital1 shared
J171 shared
Alumni Ventures Group1 shared
Gaingels1 shared
LDV Capital1 shared
Myelin VC1 shared
Last updated: 3 March 2026